Skip to main content
Product > Oncolytic Herpes Simplex Virus (oHSV) Immunotherapy

Oncolytic Herpes Simplex Virus (oHSV) Immunotherapy

oHSV are engineered viruses that attack cancer cells. They also stimulate the immune system to act against cancer cells.  Timothy P. Cripe, MD, PhD, of Nationwide Children’s Hospital and The Ohio State University has provided a suite of immunotherapy biotechnologies to Open Therapeutics for global scientific collaboration.  This suite of ViruBots have peer review published in vivo results.  Assisted by Drs. Su, Guo, Samy, Krishnamoorthy, Dr. Cripe is developing these ViruBots to target fourteen different cancer types as well as neoplasm.

 

We Believe

Open Therapeutics crowdsources orphan and dormant therapeutic intellectual properties (IP) to scientists around the world. The goal is pushing forward research that ordinarily would not generate a public value while particularly helping underserved scientists to collaborate.

How open science helps researchers succeed
Open access, open data, open source, and other open scholarship practices are growing in popularity and necessity. However, widespread adoption of these practices has not yet been achieved. One reason is that researchers are uncertain about how sharing their work will affect their careers. We review literature demonstrating that open research is associated with increases in citations, media attention, potential collaborators, job opportunities, and funding opportunities. These findings are evidence that open research practices bring significant benefits to researchers relative to more traditional closed practices.